Zealand Pharma plans IPO before Christmas  

2005.11.16
Zealand Pharma, a Danish biopharmaceutical company based near Copenhagen, has announced that it plans an IPO on Copenhagen Stock Exchange before Christmas

Zealand Pharma, a Danish biopharmaceutical company based near Copenhagen, has announced that it plans an IPO on Copenhagen Stock Exchange before Christmas. The news comes after another Danish biopharmaceutical company TopoTarget gained a listing on the Copenhagen Stock Exchange.

Rolf Sass Sørensen, stock exchange analyst at Nordea comments: "We are looking forward to Zealand Pharma seeking an IPO at Copenhagen Stock Exchange. It will contribute to the biotech culture in Denmark, and also to general knowledge building. Zealand Pharma has some interesting programmes which will probably arouse interest among investors".

Zealand Pharma was founded in 1998. The company focuses on discovery and development of novel peptide based drugs. Zealand's drug discovery has so far resulted in three compounds which are currently in clinical development. One of the compounds, a GLP-1 [Glucagon-Like-Peptide-1 – Ed] analogue for the treatment of Type 2 diabetes, has been licensed to Sanofi-Aventis. A second compound, a gap junction modifier for the prevention of ventricular arrhythmia, has been licensed to Wyeth.

Link > Zealand Pharma 

Next step

Explore business cases

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×